<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126069</url>
  </required_header>
  <id_info>
    <org_study_id>2018-10376</org_study_id>
    <nct_id>NCT05126069</nct_id>
  </id_info>
  <brief_title>Ab Interno Gelatin Microstent With MMC vs. Trabeculectomy With MMC: 3 Year Retrospective Cohort Analysis</brief_title>
  <acronym>LongGVT</acronym>
  <official_title>Longitudinal Gelatin Stent vs. Trabeculectomy (LongGVT Study): Ab Interno Gelatin Stent With Mitomycin C Versus Trabeculectomy With Mitomycin C: a Retrospective Cohort Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prism Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prism Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare 3-year post-operative efficacy and safety of standalone ab interno gelatin&#xD;
      microstent (Xen45®) versus trabeculectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center retrospective cohort study. Patients included were consecutive&#xD;
      patients from June 2012 - July 2017 who received standalone Xen45® or standalone&#xD;
      trabeculectomy. The primary outcome was time to failure, defined as intraocular pressure&#xD;
      (IOP) outside of 6mmHg - 17mmHg on no medications on two consecutive visits despite in-clinic&#xD;
      maneuvers (including needling). Secondary outcomes included IOP cutoffs of 14mmHg and 21mmHg&#xD;
      with and without medications, as well as interventions, complications, and reoperations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2018</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time to failure</measure>
    <time_frame>up to 3 years</time_frame>
    <description>defined as intraocular pressure (IOP) outside of 6mmHg - 17mmHg on no medications on two consecutive visits despite in-clinic maneuvers (including needling)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>included IOP cutoffs of 14mmHg and 21mmHg with and without medications, as well as interventions, complications, and reoperations</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Secondary outcomes included IOP cutoffs of 14mmHg and 21mmHg with and without medications, as well as interventions, complications, and reoperations.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">242</enrollment>
  <condition>Filtering Surgery</condition>
  <condition>Trabeculectomy</condition>
  <arm_group>
    <arm_group_label>Standalone Xen45</arm_group_label>
    <description>consecutive patients from June 2012 - July 2017 who received standalone Xen45®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standalone Trabeculectomy</arm_group_label>
    <description>consecutive patients from June 2012 - July 2017 who received standalone trabeculectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ab interno gelatin microstent</intervention_name>
    <description>Ab interno gelatin microstent</description>
    <arm_group_label>Standalone Xen45</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Trabeculectomy</description>
    <arm_group_label>Standalone Trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Glaucoma patients who received received a gelatin stent 45 with MMC (mitomycin C) or a&#xD;
        trabeculectomy with MMC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 30-90&#xD;
&#xD;
          -  primary or pigmentary/pseudoexfoliative open angle, primary closed angle, narrow angle&#xD;
             or combined mechanism glaucoma&#xD;
&#xD;
          -  IOP of 18-40 on maximum tolerated medical therapy&#xD;
&#xD;
          -  received a gelatin stent 45 with MMC or a trabeculectomy with MMC at Prism Eye&#xD;
             Institute from June 2012 to July 2018, and have at least 3 years of follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other forms of glaucoma&#xD;
&#xD;
          -  prior incisional glaucoma surgery&#xD;
&#xD;
          -  CPC&#xD;
&#xD;
          -  combined surgery (cataract, cornea, or retina)&#xD;
&#xD;
          -  prior corneal graft (PKP, DALK, DSAEK, DMEK)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prism Eye Institute</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 0J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://ascrs.org/clinical-education/abstracts/2021/longterm-efficacy--safety-of-standalone-ab-interno-gelatin-microstent-implantation-with-mmc-vs-trabe</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>J Liu, M Schlenker, I Ahmed. Long-Term Efficacy &amp; Safety of Standalone Ab Interno Gelatin Microstent Implantation with MMC Vs. Trabeculectomy with MMC: 3 Year Follow-up. ASCRS Conference 2021.</citation>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prism Eye Institute</investigator_affiliation>
    <investigator_full_name>Iqbal Ahmed</investigator_full_name>
    <investigator_title>Chief Innovation Officer</investigator_title>
  </responsible_party>
  <keyword>Xen</keyword>
  <keyword>Ab Interno Gelatin Microstent</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

